The FDA on January 14, 2019 approved CABOMETYX® for patients with HepatoCellular Carcinoma (HCC) who have been previously treated with NEXAVAR® (Sorafenib). CABOMETYX® is a product of Exelixis, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
Other Pages – Top Ad
Advertisement